Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.72 |
| ▸ | DHFR | P00374 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.62 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595791 | 1.00 | ERBB2 (0.72) | ERBB2DHFRKDRNPC1CSNK1D | |
| SCHEMBL5477780 | 0.90 | ERBB2 (0.76) | ERBB2DHFRKDRNPC1CSNK1D | |
| SCHEMBL5477779 | 0.90 | ERBB2 (0.76) | ERBB2DHFRKDRNPC1CSNK1D | |
| SCHEMBL7843430 | 0.90 | ERBB2 (0.76) | ERBB2DHFRKDRNPC1CSNK1D | |
| SCHEMBL5476202 | 0.86 | DHFR (0.73) | ERBB2DHFRNPC1CSNK1DCSNK1A1 | |
| SCHEMBL6405476 | 0.86 | ERBB2 (0.71) | ERBB2DHFRNPC1CSNK1DCSNK1A1 | |
| SCHEMBL5476200 | 0.86 | DHFR (0.73) | ERBB2DHFRNPC1CSNK1DCSNK1A1 | |
| SCHEMBL6405474 | 0.86 | ERBB2 (0.71) | ERBB2DHFRNPC1CSNK1DCSNK1A1 | |
| SCHEMBL7136822 | 0.85 | MAPT (0.59) | ERBB2DHFRGMNNLMNAMAPT | |
| SCHEMBL6408143 | 0.85 | ERBB2 (0.69) | ERBB2DHFRKDRNPC1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324267-B2 | Indolin-2-one derivatives as anticarcinogenic agents for treating angiogenesis, lymphangiogenesis, filariasis | FORSCHUNGZENTRUM KARLSRUHE GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324267-B2 | Indolin-2-one derivatives as anticarcinogenic agents for treating angiogenesis, lymphangiogenesis, filariasis | FORSCHUNGZENTRUM KARLSRUHE GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| EP-1406615-B1 | KINASE INHIBITORS AND THE USE THEREOF | KARLSRUHER INST TECHNOLOGIE (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-1406615-B1 | KINASE INHIBITORS AND THE USE THEREOF | KARLSRUHER INST TECHNOLOGIE (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-1476187-A4 | METHODS OF EXTENDING CORNEAL GRAFT SURVIVAL | ALLERGAN INC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20040248965-A1 | Kinase inhibitors and the use thereof | FORSCHUNGSZENTRUM KARLSRUHE GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1476187-A2 | METHODS OF EXTENDING CORNEAL GRAFT SURVIVAL | Allergan, Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1406615-A1 | KINASE INHIBITORS AND THE USE THEREOF | Forschungszentrum Karlsruhe GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030180294-A1 | Methods of extending corneal graft survival | ALLERGAN, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003072029-A2 | METHODS OF EXTENDING CORNEAL GRAFT SURVIVAL | ALLERGAN, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003007943-A1 | KINASE INHIBITORS AND THE USE THEREOF | FORSCHUNGSZENTRUM KARLSRUHE GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248965-A1 | Kinase inhibitors and the use thereof | MAP3K20, MAP3K6, MAP3K1 | ERBB2 86/4885DHFR 2413/4885KDR 857/4885 |
| US-20030180294-A1 | Methods of extending corneal graft survival | VEGFA, FLT4, FLT1 | ERBB2 426/4885DHFR 930/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.